Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures

1 Jan 2013

Abstract excerpt

On October 16, 2009, the Food and Drug Administration licensed quadrivalent human papillomavirus vaccine (HPV4; Gardasil, Merck & Co. Inc.) for use in males aged 9 through 26 years for prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11. HPV4 had been licensed previously for use in females aged 9 through 26 years for prevention of HPV 6, 11, 16, and 18-related outcomes (i.e., vaginal,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteriophages and microbial interactions
Share to Parvovirus B19 Infection Studies
Share to Polyomavirus and related diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 18981051
DOI: 10.1159/000346773

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle StructuresPMID 18981051Read ↗

Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?Semantic proximity Read ↗

Generation of Monoclonal Antibodies and Development of Sandwich ELISA for 9-valent HPV VaccinesSemantic proximity Read ↗

Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical developmentSemantic proximity Read ↗

Diseases caused by human papillomaviruses (HPV)Semantic proximity Read ↗

Developments in virus-like particle-based vaccines for infectious diseases and cancerSemantic proximity Read ↗

Potential of Recombinant Chimeric HPV16 L1/L2 VLPs Produced by Distinct Cell Lineages Such as Prophylactic Nanovaccine and Therapeutic Drug NanocarriersSemantic proximity Read ↗

Cervarix™ – a bivalent L1 virus-like particle vaccine for prevention of human papillomavirus type 16- and 18-associated cervical cancerSemantic proximity Read ↗

Developments in L2-based human papillomavirus (HPV) vaccinesSemantic proximity Read ↗

Virus‑like particles as a vaccine delivery system: Myths and factsSemantic proximity Read ↗

A Phase IV, open-label, single-arm, multicentric clinical trial for evaluation of Human Papillomavirus 9vHPV vaccine immunogenicity in Men Who Have Sex with Men living with HIV: GeSIDA Study 10017Semantic proximity Read ↗

A universal virus-like particle-based vaccine for human papillomavirus: Longevity of protection and role of endogenous and exogenous adjuvantsSemantic proximity Read ↗

The coming of age of virus-like particle vaccinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.